Status:
COMPLETED
QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study.
Lead Sponsor:
Hospital Universitari de Bellvitge
Collaborating Sponsors:
Cellestis
Conditions:
Latent Tuberculosis Infection
Eligibility:
All Genders
18-85 years
Phase:
PHASE4
Brief Summary
Hypothesis: a combined strategy of tuberculin skin test (TST) followed by QuantiFERON-TB Gold In-Tube (QFT-IT) to confirm positivity (tuberculosis infection,in contact-tracing study will allow avoidin...
Eligibility Criteria
Inclusion
- Age ≥18 years.
- Close contact of a pulmonary and/or laryngeal tuberculosis case.
- Written informed consent.
Exclusion
- HIV infection.
- Immunosuppression other than HIV, such as decompensated liver disease, chronic renal failure, corticosteroids treatment, malignancy under chemotherapy therapy.
- Prior tuberculosis or positive TST.
- Strain resistant to Isoniazid (index case).
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2016
Estimated Enrollment :
871 Patients enrolled
Trial Details
Trial ID
NCT01223534
Start Date
July 1 2010
End Date
February 1 2016
Last Update
May 27 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bellvitge University Hospital, IDIBELL
L'Hospitalet de Llobregat, Barcelona, Barcelona, Spain, 08907